Egyptian International Pharmaceutical Investments (CAI:PHAR) COGS-to-Revenue : 0.59 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments COGS-to-Revenue?

Egyptian International Pharmaceutical Investments's Cost of Goods Sold for the three months ended in Dec. 2023 was E£917 Mil. Its Revenue for the three months ended in Dec. 2023 was E£1,551 Mil.

Egyptian International Pharmaceutical Investments's COGS to Revenue for the three months ended in Dec. 2023 was 0.59.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Egyptian International Pharmaceutical Investments's Gross Margin % for the three months ended in Dec. 2023 was 40.86%.

Egyptian International Pharmaceutical Investments COGS-to-Revenue Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments COGS-to-Revenue Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.63

0.58

0.56

0.58

0.55

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.63	0.51	0.53	0.57	0.59

Egyptian International Pharmaceutical Investments COGS-to-Revenue Calculation

Egyptian International Pharmaceutical Investments's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2896.344	/	5231.666
	=	0.55

Egyptian International Pharmaceutical Investments's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	916.973	/	1550.576
	=	0.59

Egyptian International Pharmaceutical Investments (CAI:PHAR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Egyptian International Pharmaceutical Investments's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	916.973 / 1550.576
	=	40.86 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Egyptian International Pharmaceutical Investments COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.